Patents Assigned to Pfizer
  • Sorbitol dehydrogenase inhibitors
    Patent number: 6414149
    Abstract: This invention is directed to sorbitol dehydrogenase inhibitory compounds of the formula I, wherein R1, R2 and R3 are as defined in the specification. This invention is also directed to pharmaceutical compositions containing those compounds and methods of treating or preventing diabetic complications, particularly diabetic neuropathy, diabetic nephropathy, diabetic microangiopathy, diabetic macroangiopathy and diabetic cardiomyopathy by administering such compounds to a mammal suffering from diabetes and therefore at risk for developing such complications. This invention is also directed to pharmaceutical compositions comprising a combination of a compound of formula I of this invention with an aldose reductase inhibitor and to methods of treating or preventing diabetic complications therewith.
    Type: Grant
    Filed: March 29, 2000
    Date of Patent: July 2, 2002
    Assignee: Pfizer Inc.
    Inventors: Margaret Y. Chu-Moyer, Banavara L. Mylari, William J. Zembrowski
  • Indole derivatives as 5-HT1 agonists
    Patent number: 6410739
    Abstract: Compounds of the formula where W is are particularly useful in treating migraine and other disorders, such as depression, anxiety, eating disorders, obesity, drug abuse, cluster headache, pain and chronic paroxysmal hemicrania and headache associated with vascular disorders. The compounds can also be used as centrally acting antihypertensives and vasodilators.
    Type: Grant
    Filed: October 23, 2000
    Date of Patent: June 25, 2002
    Assignee: Pfizer INC
    Inventors: John Eugene Macor, Martin James Wythes
  • Child-resistant blister package
    Patent number: 6409020
    Abstract: The invention provides a child-resistant apparatus for dispensing articles which comprises a housing for retaining a blister package wherein the, housing comprises a dispensing aperture; optionally, but preferably, a blister package comprising at least one blister cell containing an article to be dispensed; and a substantially rigid backing sheet substantially co-extensive with, and substantially blocking, the dispensing aperture wherein the backing sheet comprises exposed end portions, such that pressure applied on either exposed end portion individually, or on both exposed end portions simultaneously of the backing sheet, imparts arcuate flexure thereto and dislocation thereof from the substantially co-extensive, and substantially blocking position, to a position where the dispensing aperture is unblocked permitting the article contained in the blister cell to be dispensed.
    Type: Grant
    Filed: August 4, 2000
    Date of Patent: June 25, 2002
    Assignee: Pfizer Inc.
    Inventor: Julian B. Lo
  • Aryl fused azapolycyclic compounds
    Patent number: 6410550
    Abstract: Compounds of the formula and their pharmaceutically acceptable salts, wherein R1, R2, and R3 are defined as in the specification, intermediates in the synthesis of such compounds. pharmaceutical compositions containing such compounds and methods of using such compounds, in the treatment of neurological and psychological disorders.
    Type: Grant
    Filed: September 28, 1999
    Date of Patent: June 25, 2002
    Assignee: Pfizer INC
    Inventors: Jotham Wadsworth Coe, Paige Roanne Palmer Brooks
  • Processes for preparation of Marek's disease virus using continuous avian cell lines
    Patent number: 6410297
    Abstract: The present invention relates to avian cell lines which efficiently support the growth and productive infection of Marek's Disease Virus at high titers. The present invention also relates to avian cell lines which have been engineered to support the growth and productive infection of recombinant Marek's Disease Virus at high titers. The present invention relates a process for the preparation of Marek's Disease Virus in quantities suitable for vaccine purposes.
    Type: Grant
    Filed: November 19, 1999
    Date of Patent: June 25, 2002
    Assignee: Pfizer Inc
    Inventors: Sing Rong, Michael G. Sheppard
  • Attenuated forms of bovine viral diarrhea virus
    Patent number: 6410299
    Abstract: The present invention is directed to a method of producing attenuated forms of bovine viral diarrhea (BVD) virus by mutating the Npro protease gene. The invention includes the attenuated viruses made by this method, antibodies generated using these viruses, and vaccines that can be used for immunizing cattle.
    Type: Grant
    Filed: August 29, 2000
    Date of Patent: June 25, 2002
    Assignees: Pfizer Inc., Pfizer Products Inc.
    Inventors: Xuemei Cao, Michael G. Sheppard
  • Attenuated forms of bovine viral diarrhea virus
    Patent number: 6410032
    Abstract: The present invention is directed to a method of producing attenuated forms of bovine viral diarrhea (BVD) virus by mutating the Npro protease gene. The invention includes the attenuated viruses made by the method, antibodies generated using these viruses, and vaccines that can be used for immunizing cattle.
    Type: Grant
    Filed: October 31, 2000
    Date of Patent: June 25, 2002
    Assignee: Pfizer Inc
    Inventors: Xuemei Cao, Michael G. Sheppard
  • Processes and intermediates for preparing 3(S)-[(5-chloro-1H-indole-2-carbonyl)-amino]-2(R)-hydroxy-4-phenyl-butyric acid
    Patent number: 6410750
    Abstract: The present invention provides novel processes for preparing 3(S)-[(5-chloro-1H-indole-2-carbonyl)-amino]-2(R)-hydroxy-4-phenyl-butyric acid. Also provided are novel intermediates used in those processes. Further, the 3(S)-[(5-chloro-1H-indole-2-carbonyl)-amino]-2(R)-hydroxy-4-phenyl-butyric acid prepared by the novel processes can be further reacted to yield known indole 2-carboxamides and derivatives thereof possessing glycogen phosphorylase inhibitory activity, which are useful in the treatment of mammals, especially human beings, having glycogen phosphorylase dependent diseases or conditions.
    Type: Grant
    Filed: May 5, 2000
    Date of Patent: June 25, 2002
    Assignee: Pfizer Inc.
    Inventors: Keith M. DeVries, Darrell E. Fox, Philip D. Hammen, Dennis J. Hoover, Jeffrey B. Jorgensen
  • Biaryl ether derivatives useful as monoamine reuptake inhibitors
    Patent number: 6410736
    Abstract: The present invention relates to compounds of formula I, and to their pharmaceutically acceptable salts. Compounds of formula I exhibit activity as serotonin, norepinephrine, and dopamine reuptake inhibitors and can be used in the treatment of central nervous system and other disorders.
    Type: Grant
    Filed: October 19, 2000
    Date of Patent: June 25, 2002
    Assignee: Pfizer Inc.
    Inventors: Harry R. Howard, Jr., Mavis D. Adam
  • Pyrazolopyrimidinone CGMP PDE5 inhibitors for the treatment of sexual dysfunction
    Patent number: 6407114
    Abstract: There is provided compounds of formula IA and of formula IB, wherein R1, R2, R3, R4 and A have meanings given in the description, which are useful in the curative and prophylactic treatment of a medical condition for which inhibition of a cyclic guanosine 3′,5′-monophosphate phosphodiesterase (e.g. cGMP PDE5) is desired.
    Type: Grant
    Filed: October 22, 1999
    Date of Patent: June 18, 2002
    Assignee: Pfizer Inc.
    Inventors: Mark Edward Bunnage, John Paul Mathias, Stephen Derek Albert Street, Anthony Wood
  • Neuropeptide Y antagonists
    Patent number: 6407120
    Abstract: The compound is a neuropeptide Y antagonist and is effective in treating feeding disorders, cardiovascular diseases and other physiological disorders.
    Type: Grant
    Filed: January 28, 2000
    Date of Patent: June 18, 2002
    Assignee: Pfizer Inc.
    Inventors: Philip A. Carpino, Marlys Hammond, Richard F. Hank
  • Process for the preparation of pyrazoles
    Patent number: 6407259
    Abstract: A “one-pot” process is described herein for the production of pyrazole compounds of general formula (II) comprising the steps of reacting a compound of general formula (III) with an acylating agent in the presence of a base and an optional activating agent followed by the addition of a hydrazine compound in situ.
    Type: Grant
    Filed: July 6, 2001
    Date of Patent: June 18, 2002
    Assignee: Pfizer Inc.
    Inventors: Laurence James Harris, Philip Charles Levett
  • C-4?-substituted macrolide derivatives
    Patent number: 6407074
    Abstract: This invention relates to compounds of the formula and to pharmaceutically acceptable salts thereof. The compounds of formula 1 are potent antibacterial agents that may be used to treat various bacterial infections and disorders related to such infections. The invention also relates to pharmaceutical compositions containing the compounds of formula 1 and to methods of treating bacterial infections by administering the compounds of formula 1. The invention also relates to methods of preparing the compounds of formula 1 and to intermediates useful in such preparation.
    Type: Grant
    Filed: February 16, 2000
    Date of Patent: June 18, 2002
    Assignee: Pfizer Inc
    Inventors: Brian Scott Bronk, Takushi Kaneko, Michael Anthony Letavic, Hengmaio Cheng, Edward Alan Glazer, Bingwei Vera Yang
  • 3-azabicyclo[3.1.0]hexane derivatives useful in therapy
    Publication number: 20020072616
    Abstract: Compounds of formula (I), their salts and prodrugs thereof, where the substituents are as defined herein are disclosed as opiate binding agents useful in the treatment of opiate-mediated conditions. Also described are processes for making such substances.
    Type: Application
    Filed: October 30, 2001
    Publication date: June 13, 2002
    Applicant: Pfizer Inc.
    Inventors: Bernard Joseph Banks, Robert James Crook, Stephen Paul Gibson, Graham Lunn, Alan John Pettman
  • Aralkyl and aralkylidene heterocyclic lactams and imides
    Publication number: 20020072519
    Abstract: The present invention relates to compounds of the formula 1
    Type: Application
    Filed: November 6, 2001
    Publication date: June 13, 2002
    Applicant: Pfizer Inc.
    Inventor: Harry Ralph Howard
  • Aralkyl and aralkylidene heterocyclic lactams and imides
    Patent number: 6403592
    Abstract: The present invention relates to compounds of the formula wherein R1, R2, R3, X, Y and the dashed line are defined as in the specification, to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use. These compounds are useful as psychotherapeutic agents.
    Type: Grant
    Filed: November 6, 2001
    Date of Patent: June 11, 2002
    Assignee: Pfizer INC
    Inventor: Harry Ralph Howard
  • Corticotropin releasing factor antagonists
    Patent number: 6403599
    Abstract: A method of treating, preventing or inhibiting a disorder selected from the group consisting of cardiovascular or heart related diseases such as stroke, hypertension, tachycardia, and congestive heart failure, osteoporosis, premature birth, psychosocial dwarfism, stress-induced fever, ulcer, diarrhea, post-operative ileus, and colonic hypersensitivity associated with psychopathological disturbance and stress, comprising administering to a mammal, including a human, in need of such treatment a therapeutically effective amount of a compound of the formula or a pharmaceutically acceptable salt thereof, wherein A, B, D, E, Y, Z, R3, R4, and R5 are as defined herein.
    Type: Grant
    Filed: October 30, 1996
    Date of Patent: June 11, 2002
    Assignee: Pfizer Inc
    Inventors: Yuhpyng L. Chen, Anthony A. Fossa
  • Heteroaryl-hexanoic acid amide derivatives, their preparation and their use as selective inhibitors of MIP-1-&agr; binding to its CCR 1 receptor
    Patent number: 6403587
    Abstract: Compounds of the formula wherein R1, R2, R3, R4, R5 and R6 are as described in the specification are useful to treat inflammation and other immune disorders.
    Type: Grant
    Filed: May 18, 2000
    Date of Patent: June 11, 2002
    Assignee: Pfizer Inc.
    Inventors: John Charles Kath, Matthew Frank Brown, Christopher Stanley Poss
  • Use of estrogen antagonists and estrogen agonists in inhibiting pathological conditions
    Patent number: 6403611
    Abstract: The present invention provides novel methods of inhibiting pathological conditions related to organ systems which respond to estrogen agonists comprising administering to a mammal in need of such treatment an effective amount of a compound of formula I
    Type: Grant
    Filed: March 9, 2001
    Date of Patent: June 11, 2002
    Assignee: Pfizer Inc.
    Inventors: David B. Maclean, David D. Thompson
  • Synthesis of carbamate ketolide antibiotics
    Patent number: 6403776
    Abstract: The invention relates to a method of preparing a macrolide antibiotic of the formula wherein R1, R2, R3, R4, R5 are defined above. These antibiotics are useful as antibacterial and antiprotozoal agents in mammals, including man, as well as in fish and birds. The invention also includes novel compounds made by the preparation of the macrolide antibiotic.
    Type: Grant
    Filed: July 5, 2000
    Date of Patent: June 11, 2002
    Assignee: Pfizer Inc.
    Inventors: David H. B. Ripin, Brian C. Vanderplas, Takushi Kaneko, William T. McMillen, Robert W. McLaughlin